Ikena Oncology appoints Caroline Germa as CMO; Sergio Santillana resigns

ImageneBio, Inc.

Sergio Santillana resigns as CMO effective Feb 29, 2024; will consult through Dec 31, 2024 at $500/hour.
Caroline Germa, M.D., appointed CMO effective Feb 29, 2024; brings 25+ years pharma experience.
Dr. Germa previously EVP & CMO at Transcenta, senior roles at AstraZeneca, BMS, Novartis.
Focus on advancing IK-930 (Hippo pathway) and IK-595 (RAS/RAF mutant cancers) Phase I programs.
Company on track for clinical update in second half of 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sergio Santillana

Chief Medical Officer

IMA · ImageneBio, Inc.

Effective: 2024-02-29
Filed: February 21, 2024, 6:59 PM ET

On February 20, 2024, Sergio Santillana, M.D., M.Sc., MBA, notified Ikena Oncology, Inc. (the “Company”) of his decision to resign from his role at the Company as Chief Medical Officer effective as of February 29, 2024, with his last day of employment being March 5, 2024 (the “Departure Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sergio Santillana resigned as Chief Medical Officer at ImageneBio, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On February 20, 2024, Sergio Santillana, M.D., M.Sc., MBA, notified Ikena Oncology, Inc. (the “Company”) of his decision to resign from his role at the Company as Chief Medical Officer effective as of February 29, 2024, with his last day of employment being March 5, 2024 (the “Departure Date”).

View on SEC.gov

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-041504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.